News coverage about Cytokinetics, (NASDAQ:CYTK) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytokinetics, earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.4161219735363 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
CYTK has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Cytokinetics, in a report on Sunday, September 17th. Seaport Global Securities reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Cytokinetics, in a research report on Friday, October 6th. Zacks Investment Research raised Cytokinetics, from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Tuesday, July 11th. Cowen and Company reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Cytokinetics, in a research report on Friday, August 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Cytokinetics, in a research report on Tuesday, September 26th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $21.64.
Cytokinetics, (NASDAQ:CYTK) traded up 6.25% during midday trading on Friday, reaching $13.60. The company’s stock had a trading volume of 68,132 shares. The stock’s 50-day moving average price is $14.69 and its 200 day moving average price is $14.02. The firm’s market capitalization is $729.86 million. Cytokinetics, has a 1-year low of $8.77 and a 1-year high of $17.20.
Cytokinetics, (NASDAQ:CYTK) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.04. The company had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. Equities analysts anticipate that Cytokinetics, will post ($2.49) EPS for the current fiscal year.
In other Cytokinetics, news, insider Caryn Gordon Mcdowell sold 13,181 shares of Cytokinetics, stock in a transaction that occurred on Friday, October 6th. The stock was sold at an average price of $15.49, for a total value of $204,173.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Bradley Paul Morgan sold 118,330 shares of Cytokinetics, stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $15.00, for a total value of $1,774,950.00. Following the completion of the transaction, the senior vice president now owns 63,107 shares of the company’s stock, valued at $946,605. The disclosure for this sale can be found here. Insiders sold 177,990 shares of company stock valued at $2,628,996 over the last quarter. Insiders own 7.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cytokinetics, (NASDAQ:CYTK) Earning Somewhat Positive News Coverage, Study Shows” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-cytokinetics-cytk-share-price.html.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.